German Center for Infection Research 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
9 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MVA-SARS-2-S / German Center for Infection Research, University Medical Center Hamburg-Eppendorf
NCT05950776: COVID-19 Trial of the Candidate Vaccine MVA-SARS-2-S in Adults

Withdrawn
2
NA
MVA-SARS-2-S, Placebo
Universitätsklinikum Hamburg-Eppendorf, German Center for Infection Research, Philipps University Marburg Medical Center, Ludwig-Maximilians - University of Munich, University Hospital Tuebingen, CTC-NORTH
Covid19
11/22
11/22
NCT05226390: Safety, Reactogenicity and Immunogenicity of a Novel MVA-SARS-2-ST Vaccine Candidate

Terminated
1
23
Europe
MVA-SARS-2-ST
Hannover Medical School, German Center for Infection Research, IDT Biologika, Universitätsklinikum Hamburg-Eppendorf
COVID-19 Vaccines
11/23
11/23
TherVacB / German Center for Infection Research, German Research Center for Environmental Health, Technical University of Munich
TherVacB, NCT06513286: - A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate

Not yet recruiting
1/2
89
Europe
TherVacB (HEPLISAV B), TherVacB (HBsAg ± c-di-AMP)
Michael Hoelscher, Institute of Virology Helmholtz Zentrum München Trogerstraße 30 81675 Munich, Germany
Chronic Hepatitis B
12/26
12/26
NCT05727267: A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate

Recruiting
1
24
Europe
HEPLISAV B; TherVacB, TherVacB
Universitätsklinikum Hamburg-Eppendorf, German Center for Infection Research, Medical Biometry and Epidemiology_- Universitätsklinikum Hamburg Eppendorf, Helmholtz Zentrum München, The Fraunhofer-Gesellschaft, Institute of Virology Helmholtz Zentrum München (HMGU), LMU Klinikum
Chronic Hepatitis B
02/26
06/26
NCT05051098: A Non-interventional Registry for Patients with Hepatitis B Virus Infection

Recruiting
N/A
3000
Europe
No intervention
Hannover Medical School, European Union, German Center for Infection Research, German Liver Foundation (DLS)
Hepatitis B Virus Infection
12/25
12/25
BTZ-043 / Hans Knöll Institute
NCT05382312: Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis

Recruiting
2
128
RoW
GSK3036656, Bedaquiline, Delamanid, RIFAFOUR e-275, BTZ-043
GlaxoSmithKline, Click-TB Consortium
Tuberculosis
11/24
11/24
DECISION, NCT05926466: BTZ-043 Dose Evaluation in Combination and Selection

Recruiting
2
90
RoW
BTZ-043, Bedaquiline, SIRTURO®, Delamanid, OPC-67683, Deltyba, Moxifloxacin, Lonxave
Michael Hoelscher, Radboud University Medical Center, University of California, San Francisco, University College, London
Tuberculosis, Pulmonary, Other Specified Pulmonary Tuberculosis
08/24
08/24
NCT05807399: PanACEA - STEP2C -01

Recruiting
2
270
RoW
BTZ-043, Rifampicin, Isoniazid, Pyrazinamide, Moxifloxacin
Michael Hoelscher, Radboud University Medical Center, University of California, San Francisco, University College, London
Pulmonary Tuberculosis, Other Specified Pulmonary Tuberculosis
02/25
02/25
PARADIGM4TB, NCT06114628: Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB

Recruiting
2
2500
RoW
GSK3036656, BTZ-043, Bedaquiline (B), Delamanid (D), Pretomanid (Pa), Moxifloxacin (M), Linezolid (L), Pyrazinamide (Z), Rifampicin (R), Isoniazid (H), Ethambutol (E)
University College, London, Radboud University Medical Center, London School of Hygiene and Tropical Medicine, University of Oxford, Research Center Borstel, Lygature, TASK Applied Science, Vita-Salute San Raffaele University, Helmholtz Zentrum Munchen, KNCV Tuberculosis Foundation, Critical Path Institute, European Lung Foundation, Instituto de Saude Publica da Universidade do Porto, University of Liverpool, Institut de Recherche Pour le Developpment, University of Hamburg-Eppendorf, University of California, San Francisco, TB Alliance, Find, University of Milano, University of St Andrews, Uppsala University, European Respiratory Society, Tuberculosis Network European Trialsgroup, Janssen, LP, Otsuka Pharmaceutical Development & Commercialization, Inc., German Center for Infection Research, LMU University Hospital Munich, University of Cambridge, GlaxoSmithKline
Pulmonary Tuberculosis
02/27
08/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MVA-SARS-2-S / German Center for Infection Research, University Medical Center Hamburg-Eppendorf
NCT05950776: COVID-19 Trial of the Candidate Vaccine MVA-SARS-2-S in Adults

Withdrawn
2
NA
MVA-SARS-2-S, Placebo
Universitätsklinikum Hamburg-Eppendorf, German Center for Infection Research, Philipps University Marburg Medical Center, Ludwig-Maximilians - University of Munich, University Hospital Tuebingen, CTC-NORTH
Covid19
11/22
11/22
NCT05226390: Safety, Reactogenicity and Immunogenicity of a Novel MVA-SARS-2-ST Vaccine Candidate

Terminated
1
23
Europe
MVA-SARS-2-ST
Hannover Medical School, German Center for Infection Research, IDT Biologika, Universitätsklinikum Hamburg-Eppendorf
COVID-19 Vaccines
11/23
11/23
TherVacB / German Center for Infection Research, German Research Center for Environmental Health, Technical University of Munich
TherVacB, NCT06513286: - A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate

Not yet recruiting
1/2
89
Europe
TherVacB (HEPLISAV B), TherVacB (HBsAg ± c-di-AMP)
Michael Hoelscher, Institute of Virology Helmholtz Zentrum München Trogerstraße 30 81675 Munich, Germany
Chronic Hepatitis B
12/26
12/26
NCT05727267: A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate

Recruiting
1
24
Europe
HEPLISAV B; TherVacB, TherVacB
Universitätsklinikum Hamburg-Eppendorf, German Center for Infection Research, Medical Biometry and Epidemiology_- Universitätsklinikum Hamburg Eppendorf, Helmholtz Zentrum München, The Fraunhofer-Gesellschaft, Institute of Virology Helmholtz Zentrum München (HMGU), LMU Klinikum
Chronic Hepatitis B
02/26
06/26
NCT05051098: A Non-interventional Registry for Patients with Hepatitis B Virus Infection

Recruiting
N/A
3000
Europe
No intervention
Hannover Medical School, European Union, German Center for Infection Research, German Liver Foundation (DLS)
Hepatitis B Virus Infection
12/25
12/25
BTZ-043 / Hans Knöll Institute
NCT05382312: Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis

Recruiting
2
128
RoW
GSK3036656, Bedaquiline, Delamanid, RIFAFOUR e-275, BTZ-043
GlaxoSmithKline, Click-TB Consortium
Tuberculosis
11/24
11/24
DECISION, NCT05926466: BTZ-043 Dose Evaluation in Combination and Selection

Recruiting
2
90
RoW
BTZ-043, Bedaquiline, SIRTURO®, Delamanid, OPC-67683, Deltyba, Moxifloxacin, Lonxave
Michael Hoelscher, Radboud University Medical Center, University of California, San Francisco, University College, London
Tuberculosis, Pulmonary, Other Specified Pulmonary Tuberculosis
08/24
08/24
NCT05807399: PanACEA - STEP2C -01

Recruiting
2
270
RoW
BTZ-043, Rifampicin, Isoniazid, Pyrazinamide, Moxifloxacin
Michael Hoelscher, Radboud University Medical Center, University of California, San Francisco, University College, London
Pulmonary Tuberculosis, Other Specified Pulmonary Tuberculosis
02/25
02/25
PARADIGM4TB, NCT06114628: Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB

Recruiting
2
2500
RoW
GSK3036656, BTZ-043, Bedaquiline (B), Delamanid (D), Pretomanid (Pa), Moxifloxacin (M), Linezolid (L), Pyrazinamide (Z), Rifampicin (R), Isoniazid (H), Ethambutol (E)
University College, London, Radboud University Medical Center, London School of Hygiene and Tropical Medicine, University of Oxford, Research Center Borstel, Lygature, TASK Applied Science, Vita-Salute San Raffaele University, Helmholtz Zentrum Munchen, KNCV Tuberculosis Foundation, Critical Path Institute, European Lung Foundation, Instituto de Saude Publica da Universidade do Porto, University of Liverpool, Institut de Recherche Pour le Developpment, University of Hamburg-Eppendorf, University of California, San Francisco, TB Alliance, Find, University of Milano, University of St Andrews, Uppsala University, European Respiratory Society, Tuberculosis Network European Trialsgroup, Janssen, LP, Otsuka Pharmaceutical Development & Commercialization, Inc., German Center for Infection Research, LMU University Hospital Munich, University of Cambridge, GlaxoSmithKline
Pulmonary Tuberculosis
02/27
08/27

Download Options